Advanced search
Publication Cover
Patient Related Outcome Measures Volume 10, 2019 - Issue
Submit an article Journal homepage
96
Views
1
CrossRef citations to date
0
Altmetric
Original Research

A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial

Koenraad Blot1 Alacrita Consulting Ltd, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9120-4102View further author information
ORCID Icon,
Luc Duchateau2 Department of Comparative Physiology and Biometrics, Faculty of Veterinary Medicine, Ghent University, Ghent, BelgiumView further author information
,
Benedicte Lescrauwaet3 Xintera Bvba, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0002-7976-0330View further author information
ORCID Icon,
Nilani Liyanage4 Ipsen Pharma France, Paris, FranceORCID Iconhttps://orcid.org/0000-0002-3596-8703View further author information
ORCID Icon,
David Ray5 Ipsen Biopharmaceuticals, Basking Ridge, NJ, USAORCID Iconhttps://orcid.org/0000-0003-4850-0963View further author information
ORCID Icon,
Beloo Mirakhur5 Ipsen Biopharmaceuticals, Basking Ridge, NJ, USAView further author information
&
Aaron I Vinik6 Eastern Virginia Medical School, Norfolk, VA, USAView further author information
 show all
Pages 335-343 | Published online: 29 Oct 2019

References

  • Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med. 2000;44(1):13–21.10932598
  • Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;340(11):858–868. doi:10.1056/NEJM19990318340110710080850
  • Jensen R, Doherty G. Carcinoid tumors and the carcinoid syndrome In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2001:1813–1833.
  • Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res. 1999;18(2):133–141.10464698
  • Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713–734. doi:10.1097/MPA.0b013e3181ebaffd20664471
  • Thorson A, Biorck G, Bjorkman G, Waldenstrom J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J. 1954;47(5):795–817. doi:10.1016/0002-8703(54)90152-013158264
  • Rohaizak M, Farndon JR. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours. ANZ J Surg. 2002;72(9):635–638.12269913
  • Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess. 1998;2(14):i-iv, 1–74.
  • Food and Drug Administration (FDA). Guidance for industry - Patient-reported outcome measures: use in medical product development to support labeling claims. 2009 Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM193282.pdf Accessed 714, 2016.
  • Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–977. doi:10.1016/S0140-6736(15)00817-X26703889
  • Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135. doi:10.1056/NEJMoa160742728076709
  • Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233. doi:10.1056/NEJMoa131615825014687
  • Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA, ELECT Study Group. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068–1080. doi:10.4158/EP151172.OR27214300
  • Giesinger JM, Kieffer JM, Fayers PM, et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol. 2016;69:79–88. doi:10.1016/j.jclinepi.2015.08.00726327487
  • Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461–466. doi:10.1097/MPA.0b013e318232804522422138
  • Pearman TP, Beaumont JL, Cella D, Neary MP, Yao J. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer. 2016;24(9):3695–3703. doi:10.1007/s00520-016-3189-z27029477
  • Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2017;3(1):43–53. doi:10.1200/JGO.2015.00298028717741
  • Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315(11):663–666. doi:10.1056/NEJM1986091131511022427948
  • Fisher GA Jr., Wolin EM, Liyanage N, et al. Patient-reported symptom control of diarrhea and flushing in patients with neuroendocrine tumors treated with lanreotide depot/autogel: results from a randomized, placebo-controlled, double-blind and 32-week open-label study. Oncologist. 2018;23(1):16–24. doi:10.1634/theoncologist.2017-028429038234
  • Fisher GA, Pommier RF, Wolin EM, et al. Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): subanalysis of patient-reported symptoms from the phase III elect study. J Clin Oncol. 2017;35(15_suppl):4088. doi:10.1200/JCO.2017.35.15_suppl.4088

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.